A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  R. Pfeiffer,et al.  Anal Cancer Risk Among People With HIV Infection in the United States. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jiahong Xu,et al.  Brief Report: Antibody Responses to Quadrivalent HPV Vaccination in HIV-Infected Young Women as Measured by Total IgG and Competitive Luminex Immunoassay , 2017, Journal of acquired immune deficiency syndromes.

[4]  A. Moscicki,et al.  Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine. , 2017, Vaccine.

[5]  A. Giuliano,et al.  Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. , 2015, Vaccine.

[6]  M. Einstein,et al.  Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial , 2014, Human vaccines & immunotherapeutics.

[7]  D. Galloway,et al.  Characteristics of Memory B Cells Elicited by a Highly Efficacious HPV Vaccine in Subjects with No Pre-existing Immunity , 2014, PLoS pathogens.

[8]  J. Palefsky,et al.  Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Golden,et al.  High rates of incident and prevalent anal human papillomavirus infection among young men who have sex with men. , 2014, The Journal of infectious diseases.

[10]  Richard D Moore,et al.  Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  H. Jessen,et al.  Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old , 2011, Clinical and Vaccine Immunology.

[12]  H. Jessen,et al.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. , 2011, The New England journal of medicine.

[13]  Daron G Ferris,et al.  The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay , 2011, Human vaccines.

[14]  J. Palefsky,et al.  Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. , 2010, The Journal of infectious diseases.

[15]  A. Moscicki,et al.  Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old , 2010, Journal of acquired immune deficiency syndromes.

[16]  S. Cole,et al.  A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals , 2009, Journal of acquired immune deficiency syndromes.

[17]  J. Palefsky,et al.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions , 2009, International journal of cancer.

[18]  R. Railkar,et al.  Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. , 2009, The Journal of infectious diseases.

[19]  M. Lehtinen,et al.  Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. , 2007, Vaccine.

[20]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[21]  K. Jansen,et al.  Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 , 2005, Clinical Diagnostic Laboratory Immunology.

[22]  Kathrin U. Jansen,et al.  Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay , 2003, Clinical Diagnostic Laboratory Immunology.

[23]  J. Goedert,et al.  Spectrum of AIDS-associated malignant disorders , 1998, The Lancet.

[24]  S. Zaki,et al.  Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction. , 1992, The American journal of pathology.